DEA and HHS Extend Telemedicine Controlled Substance Prescribing Flexibilities Through December 2026

What this means for your practice

This extension is a critical development for telehealth providers, medspas, and other healthcare practices that leverage telemedicine for controlled substance prescribing. It averts the anticipated 'telemedicine cliff' that would have reintroduced pre-pandemic in-person visit requirements, which could have significantly impacted patient access to necessary medications, particularly for mental health and substance use disorder treatment. Practices must recognize that this is a temporary measure, and while it provides stability for the next year, the emphasis remains on the eventual finalization of permanent rules, including the proposed 'Special Registration for Telemedicine.' It is imperative for all providers to continue adhering strictly to existing federal and state laws regarding legitimate medical purpose, licensed practice, and all other prescribing requirements, as these are not altered by the extension. Maintaining robust compliance programs and staying informed about the ongoing regulatory developments for permanent rules will be essential to ensure continued, compliant patient care.

WASHINGTON D.C. – The U.S. Department of Health and Human Services (HHS), in conjunction with the Drug Enforcement Administration (DEA), has announced a significant fourth temporary extension of telemedicine flexibilities concerning the prescribing of controlled medications. This critical action ensures that healthcare providers can continue to prescribe controlled substances via telemedicine without requiring a prior in-person medical evaluation, with the extension set to run from January 1, 2026, through December 31, 2026.

Preventing a 'Telemedicine Cliff'

The extension is designed to prevent a 'telemedicine cliff,' a situation where a sudden return to pre-pandemic restrictions would abruptly cut off access to needed medications for millions of Americans. These flexibilities were initially introduced during the COVID-19 public health emergency and have been maintained through a series of temporary extensions due to their demonstrated importance in modern healthcare delivery.

According to federal agencies, telemedicine has become a 'lifeline' for numerous patients, including seniors, rural residents, people with disabilities, and individuals receiving treatment for mental health conditions or substance use disorder. Data from 2024 alone indicated that over 7 million prescriptions for controlled medications were issued via telemedicine without an in-person visit. Past expirations of telemedicine policies have shown direct negative impacts on patient access, with one instance resulting in a 24 percent drop in fee-for-service telemedicine visits after Medicare telehealth flexibilities lapsed in September 2025.

Rationale Behind the Extension

HHS Deputy Secretary Jim O’Neill emphasized that extending these flexibilities ensures continuity of care while the agencies work to finalize permanent, commonsense policies. This approach is intended to protect patients, preserve access to vital care, and maintain strong controls against diversion of controlled substances. The Administration's commitment to patient-centered care, regulatory clarity, and public health is reflected in this decision, aiming to avoid unnecessary disruptions to treatment for millions.

Path Towards Permanent Regulations

This fourth extension grants the DEA and HHS additional time to develop and finalize permanent regulations for prescribing controlled substances via telemedicine. A key element in this process is the proposed 'Special Registration for Telemedicine,' which aims to establish clear standards for such prescribing practices while simultaneously ensuring patient safety and preventing misuse.

It is important to note that this extension does not alter existing regulatory requirements. Prescriptions for controlled substances must still be issued for legitimate medical purposes, by licensed practitioners, and in full compliance with all applicable federal and state laws. Providers are reminded that adherence to these foundational principles remains paramount.

Impact on Healthcare Practices

For telehealth brands, medspas, dental practices, chiropractic offices, and other healthcare businesses that engage in prescribing controlled medications, this extension offers crucial temporary relief and predictability. It allows these practices to continue their current models of care delivery for controlled substances without immediate disruption. However, the temporary nature of this extension underscores the ongoing need for vigilance and preparedness for the eventual implementation of permanent regulations. Practices should actively monitor updates from DEA and HHS regarding the 'Special Registration for Telemedicine' and other forthcoming rules to ensure future compliance. Maintaining robust internal compliance programs and ensuring all practitioners are fully aware of federal and state prescribing guidelines remains critical during this transitional period.

Key Facts

| Detail | Value | |---|---| | Action | Fourth temporary extension of telemedicine flexibilities for controlled substance prescribing | | Agencies | U.S. Department of Health and Human Services (HHS) and Drug Enforcement Administration (DEA) | | Extension Period | January 1, 2026, through December 31, 2026 | | Purpose | Prevent disruptions in patient care while permanent rules are finalized | | Key Future Initiative | Proposed Special Registration for Telemedicine | | Current Requirements | Prescriptions must be for legitimate medical purposes, by licensed practitioners, and in compliance with federal and state law. |

Frequently Asked Questions

What is the main change announced by HHS and DEA?

The main change is a temporary extension of telemedicine flexibilities for prescribing controlled medications without a prior in-person visit.

How long will these telemedicine flexibilities last?

These flexibilities are extended from January 1, 2026, through December 31, 2026.

Why did HHS and DEA decide to extend these flexibilities?

The extension aims to prevent disruptions in care for millions of Americans, including vulnerable populations like seniors, rural residents, and individuals receiving treatment for mental health conditions or substance use disorder, while permanent regulations are finalized.

Do these extended flexibilities change existing legal requirements for prescribing controlled substances?

No, the extension does not change existing requirements that prescriptions must be issued for legitimate medical purposes, by licensed practitioners, and in compliance with all federal and state laws.

What are HHS and DEA planning for permanent rules regarding telemedicine prescribing of controlled substances?

The federal agencies are working to finalize permanent regulations, including the proposed Special Registration for Telemedicine, which would establish clear standards for prescribing controlled substances via telemedicine while preserving patient safety and preventing misuse.

Source: hhs.gov — DEA and HHS Finalize Telemedicine Rules for Buprenorphine and VA Patients